Full Press Release Details
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients.
BIIB
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Key Takeaway: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Price reaction · baseline $150.71 (2025-03-10 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
-4.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis